Mycophenolate Mofetil: Clinical Overview
Indications
Mycophenolate mofetil (MMF) is FDA-approved for prophylaxis of organ rejection in solid organ transplantation (renal, cardiac, and hepatic) in combination with other immunosuppressants 1. Beyond transplantation, MMF has established roles in autoimmune conditions including lupus nephritis and ANCA-associated vasculitis 2, 3.
Specific Indications:
- Solid organ transplantation: Renal, cardiac, and hepatic transplants (adults and pediatrics ≥3 months) 1, 4
- Lupus nephritis: Maintenance therapy for proliferative LN after induction 2
- ANCA-associated vasculitis: Alternative maintenance therapy for patients intolerant of azathioprine 3
Dosing Guidelines
Transplantation Dosing (FDA-Approved)
Adults:
- Renal transplant: 1 g orally twice daily (2 g/day total) 1
- Note: 1.5 g twice daily (3 g/day) showed no efficacy advantage and worse safety profile
- Cardiac transplant: 1.5 g orally twice daily (3 g/day total) 1
- Hepatic transplant: 1.5 g orally twice daily (3 g/day total) 1
Pediatrics (3 months to 18 years):
- 600 mg/m² twice daily (maximum 2 g/day) using oral suspension 1
- BSA 1.25-1.5 m²: 750 mg capsules twice daily
- BSA >1.5 m²: 1 g capsules/tablets twice daily
- For cardiac/hepatic transplants: Starting dose 600 mg/m² up to maximum 900 mg/m² twice daily 4
Autoimmune Disease Dosing
Lupus Nephritis (Maintenance):
- 750-1000 mg twice daily in early maintenance phase 2
- Continue until complete response achieved, then taper
- Total duration of immunosuppression (induction + maintenance) should be ≥36 months 2
ANCA-Associated Vasculitis (Maintenance):
- 2000 mg/day in divided doses 3
- May increase to 3000 mg/day for poor treatment response 3
- Continue at complete remission for 2 years 3
Administration Considerations
Administer on an empty stomach for optimal absorption (food decreases Cmax by 40%) 1. However, in stable renal transplant patients, may give with food if necessary. Start as soon as possible after transplantation 1.
Contraindications and Critical Warnings
Absolute Contraindications:
- Hypersensitivity to mycophenolate mofetil, mycophenolic acid, or any component
- Pregnancy (Category D): Associated with 45% spontaneous abortion rate and 22% congenital malformations in exposed pregnancies 1
Black Box Warnings:
Pregnancy Risk:
- Females of reproductive potential must use two forms of contraception starting before therapy, during therapy, and for 6 weeks after discontinuation 1
- Hormonal contraceptives should be combined with barrier methods due to potential interaction 1
- Report any pregnancy exposure to Mycophenolate Pregnancy Registry (1-800-617-8191) 1
Malignancy Risk:
- Increased risk of lymphomas and other malignancies, particularly skin cancers 5
Serious Infections:
- Increased susceptibility to opportunistic infections 5
Dose Adjustments
Renal Impairment:
- **GFR <25 mL/min/1.73 m²**: Avoid doses >1 g twice daily outside immediate post-transplant period 1
- No adjustment needed for delayed graft function immediately post-transplant 1
- For lupus nephritis with significant CKD: Dose reduction may be needed due to increased susceptibility to MPA adverse effects 2
Hepatic Impairment:
- No dose adjustment recommended for severe hepatic parenchymal disease in renal patients 1
- Insufficient data for cardiac/hepatic transplant patients with severe hepatic disease 1
Neutropenia:
- If ANC <1.3 × 10³/µL: Interrupt dosing or reduce dose 1
Elderly:
- Use standard adult dosing but monitor closely for increased adverse reactions 1
Monitoring Requirements
Laboratory Monitoring:
- Complete blood count (CBC): Weekly during first month, twice monthly for months 2-3, then monthly through first year 1
- Hold or reduce dose if ANC <1.3 × 10³/µL
- Renal function: Monitor regularly, especially when co-administered with nephrotoxic drugs
- Hepatic function: Periodic monitoring
Therapeutic Drug Monitoring (TDM):
- Not routinely required but may be helpful in specific situations 2, 6:
- Unsatisfactory treatment response
- Patients at increased risk of toxicities
- Disease flares (preliminary data associate flares with low MPA exposure) 2
- Target MPA AUC: Varies by indication and concomitant immunosuppression 6
Clinical Monitoring:
- Infection surveillance: Monitor for signs/symptoms of opportunistic infections
- Malignancy screening: Regular skin examinations and age-appropriate cancer screening
- Pregnancy testing: Before initiation in females of reproductive potential and periodically during therapy 1
Critical Drug Interactions
Significant Interactions Requiring Dose Adjustment or Avoidance:
Cholestyramine: Decreases MPA AUC by ~40% through interruption of enterohepatic recirculation—avoid coadministration 1
Cyclosporine: Reduces MPA exposure by 30-50% by inhibiting enterohepatic recirculation 1
- When switching from cyclosporine to tacrolimus or belatacept, expect increased MPA exposure
Telmisartan: Decreases MPA concentrations by ~30%—monitor closely 1
Norfloxacin + Metronidazole combination: Reduces MPA AUC by 33%—avoid this specific combination 1
Sevelamer and calcium-free phosphate binders: Decrease MPA Cmax by 36% and AUC by 26% 1
- Do not administer simultaneously
- Give phosphate binders 2 hours after MMF 1
Ganciclovir/Valganciclovir: Both compete for tubular secretion—monitor carefully in renal impairment 1
Interactions Without Dose Adjustment Needed:
- Trimethoprim/sulfamethoxazole: No effect on MPA bioavailability 1
- Tacrolimus: Does not interfere with MPA enterohepatic recirculation (unlike cyclosporine)
Common Pitfalls and Caveats
Pregnancy prevention failure: The most critical error is inadequate contraception counseling. Ensure two methods including barrier contraception even with hormonal methods 1.
Cyclosporine switching: When converting from cyclosporine to tacrolimus-based regimens, MPA exposure increases 30-50%. Monitor for toxicity and consider empiric dose reduction 1.
Phosphate binder timing: Administering sevelamer simultaneously with MMF significantly reduces absorption. Strict 2-hour separation is essential 1.
Neutropenia management: Do not continue full-dose MMF with ANC <1.3 × 10³/µL. Dose reduction or interruption is mandatory 1.
Duration errors in autoimmune disease: For lupus nephritis, total immunosuppression duration must be ≥36 months. Premature withdrawal increases relapse risk 2.
Missed dose handling: If near next scheduled dose, skip the missed dose—do not double up 1.
Breastfeeding: MMF is excreted in rat milk; discontinue nursing or discontinue drug 1.